Hypera Pays $825m For Takeda LatAm Portfolio
Post-Shire Divestments Reach $7.4bn
Major new portfolio divestment, along with Deerfield site sale, form part of ongoing effort to pay down Shire-related debt and focus on novel drugs.
You may also be interested in...
US biotech expands 2017 collaboration with Alnylam and inks collaboration with WuXi. Plus deals involving AbbVie, Allergan, Amazon, Thermo Fisher, Qiagen, Boehringer Ingelheim, Trutino, Taiho, Arcus, Eisai, Fuji Yakuhin, Hikma, Glenmark, Hanmi, GC, Bayer, GW.
In a continued effort to pay down its debt pile from the acquisition of Shire, Takeda is to offload around 30 selected OTC and Rx products in certain Middle East and other emerging markets to private Swiss group Acino.
Takeda is to close down and relocate one of its main US sites, with unspecified job losses, as it plans post-Shire restructuring, while in Japan vocal opposition to the acquisition rises.